Full-Time
Registered Dietitian
L-Nutra
51-200 employees
Develops plant-based health tech for longevity
No salary listed
Remote in USA
Remote
Remote within the United States, with some travel required to Miami, Florida.
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to L-Nutra
See people who can refer or advise you
- A bachelor's degree in a relevant field is required.
- At least 3 years of experience as a Registered Dietitian is required.
- Spanish fluency is required because most patients will be Spanish-speaking.
- Written, verbal, and interpersonal communication skills in English and Spanish are required.
- High proficiency in time management, organization, and prioritization is required.
- Manage a dedicated panel of clients aiming to prevent, manage, or reverse chronic metabolic conditions.
- Deliver virtual counseling through video, phone, and secure messaging on a HIPAA-compliant platform.
- Apply motivational interviewing to support behavior change, increase engagement, and improve outcomes.
- Collaborate with the Chief Medical Officer during weekly clinical reviews.
- Coordinate with healthcare providers to gather laboratory results, glucose-monitoring data, and medication adjustments.
- Create educational materials, evidence-based handouts, and creative content for members.
- Develop monthly blog posts and multimedia resources tied to the proprietary technology and diabetes program.
- Contribute to social media communities and member-engagement initiatives.
- Identify opportunities to enhance the member journey and recommend improvements.
- Lead group coaching.
- Develop and present webinars, including possible in-person presentations.
- Maintain timely and accurate documentation of all counseling sessions, including completed, cancelled, and rescheduled sessions.
- Support coaching initiatives and compliance expectations weekly.
- Provide feedback to improve the integration of coaching services within the software platform.
- Partner with cross-functional teams to strengthen program execution as the company scales.
- Represent the company's values, mission, and clinical excellence in every interaction.
- Act as a trusted voice for prospective members and healthcare providers learning about the program.
- Work occasional pre-scheduled hours outside standard business hours to support member needs.
- Florida Registered Dietitian licensure is preferred.
- Experience in healthcare, wellness, or consumer health products is preferred.
- Familiarity with patient-centric digital healthcare models is preferred.
L-Nutra develops plant-based health tech solutions that aim to extend healthspan and longevity through its Fasting Mimicking Technology (FMT) platform. The core product line consists of plant-based regimens designed to mimic the effects of fasting, triggering cellular rejuvenation and supporting healthy aging. The solutions are consumed continually and may be complemented by AI-driven lifestyle education and collaboration with health professionals. The company differentiates itself by combining science-backed fasting-mimicking protocols with education and care coordination, not only selling products but also guiding users toward proactive health management. Its goal is to shift the health system from reactive sick care to proactive health care focused on prevention, longevity, and improved well-being."
Company Size
51-200
Company Stage
Series D
Total Funding
$47M
Headquarters
Los Angeles, California
Founded
2009
Get referred to L-Nutra
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 7 2026 IDS gave L-Nutra exclusive UAE distribution across Mubadala Bio.
- January 2026 Mubadala invested $36.5 million for Abu Dhabi manufacturing and MENA reach.
- June 2026 Prolon launched Almost Forever, widening consumer reach and brand authority.
What critics are saying
- The 2024 Proposition 65 settlement over lead in ProLon shakes exposes compliance risk.
- FDA scrutiny or another Prop 65 action can halt ProLon sales and damage trust.
- If Abu Dhabi manufacturing stalls, expansion capital burns and international growth collapses.
What makes L-Nutra unique
- L-Nutra combines 47 clinical trials, 137 patents, and fasting-mimicking nutrition.
- Mubadala backed its January 2026 Series D, validating sovereign-level strategic relevance.
- L-Nutra sells physician-integrated ProLon through clinics like Parsley Health and Lindora.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Company Equity
Remote Work Options
Flexible Work Hours
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -4%Agreement between 'Al-Ittihad for Pharmaceuticals' and 'L-Nutra' to expand healthy nutrition solutions in the UAE * Thursday, May 7, 2026 2:49 PM * 2 minutes read * Summary * A+ Abu Dhabi, May 7 / WAM / Al-Ittihad for Pharmaceuticals, a subsidiary of the pharmaceutical logistics hub at 'Mubadala Bio', signed an exclusive distribution and promotion agreement with 'L-Nutra', a company specializing in nutrition technologies and healthy longevity, during its participation in the 'Make it in the Emirates 2026' exhibition. The aim is to expand access to medical nutrition solutions and dietary therapies supporting healthy longevity in the UAE. The agreement was signed in the presence of Ismail Ali Abdullah, Executive Director of the Strategic Complexes Unit of the Investment Sector in the UAE at Mubadala, and was signed by Hamad Hussein Al Marzouqi, Deputy CEO of Mubadala Bio, and Joseph Anton, CEO of L-Nutra. Under the agreement, Al-Ittihad for Pharmaceuticals will be responsible for the exclusive marketing and distribution of L-Nutra's products for nutrition supporting healthy longevity within the country, including 'Prolon' products, one of the innovative dietary solutions designed to provide a fasting-mimicking dietary approach. This partnership is part of Mubadala Bio's strategy to expand its portfolio of advanced health solutions and enhance access to healthy longevity products, supporting its directions towards developing the pharmaceutical industry sector by providing innovative and modern health products. Ismail Ali Abdullah, Head of the Strategic Complexes Unit within the Investment Sector in the UAE at Mubadala, said that this partnership is a natural extension of Mubadala's investment in L-Nutra and reflects Abu Dhabi's ambition to establish itself as a regional hub for the pharmaceutical industry. He pointed out that expanding access to the company's products in the UAE contributes to providing innovative health solutions to individuals with greater efficiency and ease. For his part, Hamad Hussein Al Marzouqi, Deputy CEO of Mubadala Bio, affirmed that the agreement reflects the company's ambition to lead in areas that shape the future of the pharmaceutical industry. He explained that cooperation with L-Nutra contributes to expanding access to medical nutrition solutions and dietary treatments related to healthy longevity within the country, thereby enhancing Mubadala Bio's role as a trusted partner in supporting quality of life and sustainable health. Joseph Anton, CEO of L-Nutra, said that cooperation with Al-Ittihad for Pharmaceuticals, a subsidiary of Mubadala Bio, represents an important step to expand the company's presence in the UAE. He stressed that the agreement supports growth plans and allows access to nutrition solutions supporting healthy longevity for a broader segment of individuals. R.A. / Z.Z. / S.R. * Economy * Health * United Arab Emirates (UAE) * Abu Dhabi * Make it in the Emirates 2026 exhibition * L-Nutra * Al-Ittihad for Pharmaceuticals * Mubadala Bio The news is also available in the following languages:
L-Nutra CEO Joseph Antoun has been named a 2026 Life Sciences Visionary by LA Times Studios for advancing longevity science into a clinically validated medical discipline. The recognition highlights his leadership in transforming healthcare from reactive treatment to prevention-focused care. Under Antoun's direction, L-Nutra has generated over $250 million in revenue and built a portfolio of 221 licensed patents in longevity-focused nutrition. The company has conducted clinical research demonstrating that fasting-mimicking nutrition can activate autophagy and cellular rejuvenation in humans, translating Nobel Prize-winning research into practical applications. L-Nutra partners with medical centres to deliver nutrition therapies addressing chronic conditions including diabetes and cardiovascular disease. Antoun also serves as Co-Director of the Center for Health Policy at the University of Chicago.
L-Nutra CEO Dr Joseph Antoun has been named a 2026 Life Sciences Visionary by LA Times Studios for advancing longevity as a clinical discipline. The recognition highlights his work transforming healthcare from reactive treatment to prevention-focused care centred on metabolic health and healthy aging. Under Antoun's leadership, L-Nutra has generated over $250 million in revenue and built a portfolio of 221 licensed patents in longevity-focused nutrition. The company recently demonstrated that fasting-mimicking nutrition can activate autophagy and cellular rejuvenation in humans, translating Nobel Prize-winning research into practical applications. L-Nutra partners with medical centres to deliver nutrition therapies addressing chronic conditions including diabetes and cardiovascular disease. Antoun also serves as Co-Director of the Center for Health Policy at the University of Chicago.
L-Nutra named Innovator Partner for the Longevity Show 2026. Precision nutrition pioneer L-Nutra will bring fasting-mimicking science and clinically validated longevity programs to the Longevity Show. The Longevity Show 2026 has announced L-Nutra as an Innovator Partner, signaling the rising influence of evidence-based nutrition in extending healthspan and tackling the chronic diseases of aging. Nutrition has always been medicine's awkward middle child - everywhere at once, yet oddly ignored. We've seen it relegated to flimsy patient pamphlets or over-analyzed in academic journals, but it's rarely been treated with the kind of systematic, pharmaceutical-grade discipline that actually moves the needle. Nutrition as infrastructure. Andrea Ghirardi, L-Nutra's CEO EMEA, isn't heading to the Business Stage to talk about lifestyle tweaks or wellness trends. Instead, he's framing precision nutrition as a piece of essential infrastructure - a strategic necessity for societies that are rapidly graying. This shift from 'nice-to-have' to 'must-hire' continues in a closed-door roundtable, where industry leaders will hammer out how to actually bake metabolic resilience into formal healthcare. For those who want to see the mechanics in action, L-Nutra's floor presence moves past the white papers to show how fasting-mimicking and medical nutrition programs work in practice. Behind the brand sits a formidable evidence base. In partnership with 18 global university research centers, L-Nutra has developed formulations inspired by precision nutrition and powered by cellular longevity science; programs supported by 47 clinical trials and protected by 137 granted patents. Numbers matter here - because in a sector crowded with biohacks and bravado, validation is currency. Metabolic levers, pulled on purpose. The engine driving L-Nutra is its fasting-mimicking technology - essentially a way to hack the body's biology. It's designed to pull the same metabolic levers as a water-only fast, triggering things like autophagy and IGF-1 modulation, but without the safety risks or the sheer misery of actually starving. It's less about 'dieting' and more about precisely re-tuning nutrient-sensing networks to spark cellular repair. The flagship Prolon longevity program, alongside medical nutrition therapies targeting chronic conditions, reflects a reframing that feels quietly radical: food not as fuel alone, nor as wellness theatre, but as programmable intervention. "L-Nutra is a science-backed innovator transforming lives through its pioneering fasting-mimicking products," said Phil Newman, cofounder of the Longevity Show and CEO of Longevity.Technology. "The company works closely with clinics and medical partners worldwide to deliver the proven metabolic health benefits of fasting in a clinically supported way. My family and I have personally experienced the benefits of the Fasting Mimicking Diet, and I'm proud that L-Nutra is supporting our show in bringing this important science and technology to the longevity community and broader public." As health systems strain under the compounding burdens of metabolic dysfunction, oncologic risk and neurodegenerative decline, the notion that nutrition might serve as frontline infrastructure - preventative, therapeutic and economically strategic - is gaining traction. L-Nutra's presence at the Longevity Show is not merely sponsorship; it is signal. A marker of where the field is heading. Food as code. Fasting as platform. Longevity, engineered. To learn more about partnership and exhibitor opportunities at The Longevity Show 2026, contact the Sponsor & Exhibitor team. The Longevity Show opens its doors on 26-27 June 2026 at Tobacco Dock, London. Early bird tickets for all tiers are now available at www.longevityshow.com until 28 February 2026.
L-Nutra raises additional $36.5M in Series D funding. L-Nutra, a Los Angeles, CA-based nutri-technology company advancing science-driven nutrition for longevity and nutrition as medicine, raised additional $36.5M in its Series D funding. The investment was led by Mubadala Investment Company. The company intends to use the funds to expand operations and its development efforts. Led by MD, PhD, Chairman and CEO Joseph Antoun, L-Nutra is a nutri-technology company that focuses on the discovery, design, and commercialization of Nutrition for Longevity and Nutrition as Medicine programs that enhance human healthspan and drive remission in chronic diseases. In partnership with 18 global university research centers, it has developed nutrition formulations inspired by precision nutrition and empowered by cellular longevity science. Supported by 47 clinical trials and 137 granted patents, L-Nutra improves the nutrition's research to treat aging and chronic disease. Its programs, including Prolon for longevity and its medical nutrition therapies for chronic conditions, are designed to optimize safety, nourishment, and therapeutic benefit while implementing health outcomes across populations.